July news roundup
First external contract win for Inaphaea BioLabs
We were delighted to announce that our subsidiary company Inaphaea BioLabs signed a Master Services Agreement and Project Statement of Work with a UK-based biotech company.
This defined work programme, which involves a multi-stage project and is expected to complete at the end of September 2023, is investigating possible anti-cancer properties of a range of novel molecules using a phenotypic assay and will benefit from the use of patient-derived cells (“PDCs”) from Inaphaea’s biobank, recently acquired from the liquidated assets of Imagen.
In addition, Inaphaea has commenced studies on internal ValiRx assets VAL301 and Cytolytix CLX001, thereby reducing third-party testing costs and reducing potential for delays.
Find out more about the announcement here.
ValiRx and Inaphaea teams attend On Helix
On 6 July, ValiRx CEO Dr Suzy Dilly, Corporate Development Manager Mark Treharne, and Inaphaea's Head of Strategic Development, Dr Andrew Carnegie attended On Helix in Cambridge.
The conference, which has become a staple in the life sciences events calendar, addresses the key trends in bio innovation, from developments in life science and technology research to their translation into new diagnostics, prevention tools or treatments.
As a member of One Nucleus, Inaphaea BioLabs was a sponsor of On Helix and had a booth at the event, which attracted a number of visitors who we enjoyed speaking to about all things cell assays, oncology, and women’s health.
Meet Inaphaea BioLabs’ Lead Scientist
We also sat down with Inaphaea BioLabs’ Lead Scientist Melissa Barr to find out more about her background and experience and her ambitions for the new laboratory.
At Inaphaea, Melissa’s role involves collaborating with external clients as well as the ValiRx team to deliver pre-clinical drug discovery projects largely in oncology and women’s health.
Read the article here.
Inaphaea BioLabs launch event
We are now less than two months away from the launch of Inaphaea BioLabs!
On 26 September, we are hosting an event with BioNow to mark Inaphaea’s official launch at MediCity in Nottingham. The afternoon event will include a tour of the labs and the recently acquired assets from Imagen Therapeutics, alongside talks from keynote speakers, networking opportunities, and a buffet lunch.
Register for the event on BioNow's website here.
